Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) (TSE:AUP) Director Kevin Tang acquired 516,439 shares of the stock in a transaction dated Friday, February 27th. The shares were purchased at an average price of $13.99 per share, for a total transaction of $7,224,981.61. Following the completion of the purchase, the director directly owned 11,845,939 shares in the company, valued at $165,724,686.61. The trade was a 4.56% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.
Aurinia Pharmaceuticals Stock Down 0.4%
Shares of AUPH stock opened at $14.15 on Wednesday. Aurinia Pharmaceuticals Inc has a 52-week low of $6.82 and a 52-week high of $16.54. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of 6.80 and a beta of 1.53. The firm's 50-day moving average is $14.88 and its 200-day moving average is $13.96. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.76 and a current ratio of 5.25.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) (TSE:AUP) last posted its quarterly earnings results on Thursday, February 26th. The biotechnology company reported $1.53 EPS for the quarter, topping analysts' consensus estimates of $0.21 by $1.32. The business had revenue of $77.11 million during the quarter, compared to analysts' expectations of $74.70 million. Aurinia Pharmaceuticals had a return on equity of 27.47% and a net margin of 101.46%. Sell-side analysts predict that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AUPH. Corient Private Wealth LLC increased its position in Aurinia Pharmaceuticals by 864.5% during the 4th quarter. Corient Private Wealth LLC now owns 275,472 shares of the biotechnology company's stock worth $4,394,000 after buying an additional 246,912 shares during the period. nVerses Capital LLC acquired a new position in shares of Aurinia Pharmaceuticals in the fourth quarter valued at about $406,000. Uniplan Investment Counsel Inc. increased its position in Aurinia Pharmaceuticals by 31.3% during the fourth quarter. Uniplan Investment Counsel Inc. now owns 120,202 shares of the biotechnology company's stock worth $1,917,000 after acquiring an additional 28,645 shares during the period. Voloridge Investment Management LLC increased its position in Aurinia Pharmaceuticals by 44.3% during the fourth quarter. Voloridge Investment Management LLC now owns 739,444 shares of the biotechnology company's stock worth $11,794,000 after acquiring an additional 226,875 shares during the period. Finally, Wellington Management Group LLP raised its stake in Aurinia Pharmaceuticals by 4.7% in the 4th quarter. Wellington Management Group LLP now owns 53,721 shares of the biotechnology company's stock worth $857,000 after purchasing an additional 2,421 shares in the last quarter. 36.83% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research firms recently weighed in on AUPH. Leerink Partners lowered Aurinia Pharmaceuticals from an "outperform" rating to a "market perform" rating and boosted their target price for the stock from $15.00 to $16.00 in a report on Wednesday, December 3rd. Jefferies Financial Group raised shares of Aurinia Pharmaceuticals from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $10.00 to $21.00 in a research report on Friday, November 7th. Royal Bank Of Canada reiterated a "sector perform" rating and issued a $15.00 price objective (up from $9.00) on shares of Aurinia Pharmaceuticals in a report on Wednesday, November 5th. Weiss Ratings reissued a "hold (c)" rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Bloom Burton cut shares of Aurinia Pharmaceuticals from a "moderate buy" rating to a "hold" rating in a research note on Wednesday, November 5th. Two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Aurinia Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $17.25.
Read Our Latest Stock Report on Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Company Profile
(
Get Free Report)
Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company's proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.
The company's lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
